Osborn Williams & Donohoe LLC Sells 2,195 Shares of Bristol-Myers Squibb Co (NYSE:BMY)

Osborn Williams & Donohoe LLC reduced its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 3.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 64,061 shares of the biopharmaceutical company’s stock after selling 2,195 shares during the quarter. Osborn Williams & Donohoe LLC’s holdings in Bristol-Myers Squibb were worth $2,905,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in BMY. FMR LLC grew its position in shares of Bristol-Myers Squibb by 313.9% during the 1st quarter. FMR LLC now owns 40,851,887 shares of the biopharmaceutical company’s stock worth $1,949,043,000 after purchasing an additional 30,981,844 shares in the last quarter. Norges Bank acquired a new stake in shares of Bristol-Myers Squibb during the 4th quarter worth approximately $797,038,000. Janus Henderson Group PLC boosted its position in shares of Bristol-Myers Squibb by 15.5% during the 1st quarter. Janus Henderson Group PLC now owns 9,196,512 shares of the biopharmaceutical company’s stock worth $438,767,000 after acquiring an additional 1,231,639 shares in the last quarter. Legal & General Group Plc boosted its position in shares of Bristol-Myers Squibb by 5.9% during the 4th quarter. Legal & General Group Plc now owns 8,568,445 shares of the biopharmaceutical company’s stock worth $445,300,000 after acquiring an additional 474,820 shares in the last quarter. Finally, Nordea Investment Management AB boosted its position in shares of Bristol-Myers Squibb by 380.2% during the 1st quarter. Nordea Investment Management AB now owns 6,252,847 shares of the biopharmaceutical company’s stock worth $298,324,000 after acquiring an additional 4,950,748 shares in the last quarter. 77.71% of the stock is currently owned by hedge funds and other institutional investors.

Several research firms recently issued reports on BMY. Argus lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $46.36 price target on the stock. in a research report on Monday, May 20th. BMO Capital Markets raised their target price on shares of Bristol-Myers Squibb from $62.00 to $63.00 and gave the company an “outperform” rating in a research report on Wednesday, April 17th. UBS Group cut their target price on shares of Bristol-Myers Squibb from $55.00 to $51.00 and set a “neutral” rating on the stock in a research report on Thursday, June 13th. ValuEngine lowered shares of Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a research report on Tuesday, July 2nd. Finally, Barclays upgraded shares of Bristol-Myers Squibb from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $53.00 to $55.00 in a research report on Friday, May 3rd. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and eight have assigned a buy rating to the company. Bristol-Myers Squibb has a consensus rating of “Hold” and an average target price of $55.45.

In other Bristol-Myers Squibb news, Director Robert J. Bertolini purchased 11,000 shares of the company’s stock in a transaction dated Wednesday, July 31st. The stock was purchased at an average price of $44.72 per share, with a total value of $491,920.00. Following the completion of the purchase, the director now owns 11,397 shares of the company’s stock, valued at $509,673.84. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Karen Murphy Santiago sold 3,065 shares of the firm’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $47.56, for a total transaction of $145,771.40. Following the transaction, the insider now directly owns 3,066 shares of the company’s stock, valued at approximately $145,818.96. The disclosure for this sale can be found here. 0.13% of the stock is currently owned by company insiders.

Shares of BMY stock traded up $0.52 during trading hours on Wednesday, hitting $46.21. 975,282 shares of the company’s stock traded hands, compared to its average volume of 14,899,019. The firm has a 50 day moving average price of $45.49. The stock has a market cap of $74.74 billion, a PE ratio of 11.61, a PEG ratio of 2.28 and a beta of 0.73. Bristol-Myers Squibb Co has a 12 month low of $42.48 and a 12 month high of $63.69. The company has a current ratio of 3.88, a quick ratio of 3.75 and a debt-to-equity ratio of 1.51.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, July 25th. The biopharmaceutical company reported $1.18 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.06 by $0.12. The firm had revenue of $6.27 billion during the quarter, compared to the consensus estimate of $6.10 billion. Bristol-Myers Squibb had a net margin of 26.14% and a return on equity of 47.63%. The company’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same quarter last year, the firm earned $1.01 earnings per share. Equities analysts forecast that Bristol-Myers Squibb Co will post 4.26 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, August 1st. Stockholders of record on Friday, July 5th were paid a dividend of $0.41 per share. This represents a $1.64 annualized dividend and a dividend yield of 3.55%. The ex-dividend date was Wednesday, July 3rd. Bristol-Myers Squibb’s payout ratio is currently 41.21%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Recommended Story: The Discount Rate – What You Need to Know

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.